Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis—a proof of principle and exploratory trial: is dose tapering practical in good responders?

OBJECTIVES: RA patients receiving TNF inhibitors (TNFi) usually maintain their initial doses. The aim of the Optimizing Treatment with Tumour Necrosis Factor Inhibitors in Rheumatoid Arthritis trial was to evaluate whether tapering TNFi doses causes loss of clinical response. METHODS: We enrolled RA...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibrahim, Fowzia, Lorente-Cánovas, Beatriz, Doré, Caroline J, Bosworth, Ailsa, Ma, Margaret H, Galloway, James B, Cope, Andrew P, Pande, Ira, Walker, David, Scott, David L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722050/
https://www.ncbi.nlm.nih.gov/pubmed/28968858
http://dx.doi.org/10.1093/rheumatology/kex315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722050/
https://www.ncbi.nlm.nih.gov/pubmed/28968858
http://dx.doi.org/10.1093/rheumatology/kex315

Ejemplares similares